Streamex Corp. (STEX): Nasdaq/NYSE listing notice — BioSig receives Nasdaq delisting notice for bid price under $1.00

Streamex Corp.

Nasdaq letter dated Sept 6, 2023: closing bid price below $1.00 for 30 consecutive business days.
Company has 180-day compliance period until March 4, 2024 to regain minimum bid price requirement.
To cure, common stock must close at $1.00 for at least ten consecutive business days.
If not cured, may qualify for second 180-day period by meeting other listing standards and planning reverse stock split.
No immediate effect on trading; shares continue listing on Nasdaq Capital Market.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Streamex Corp. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

September 6, 2023, BioSig Technologies, Inc. (the “Company”) received a letter from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock for the 30 consecutive business days between July 25, 2023, to September 5, 2023, the Company did not meet the minimum bid price of $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2). The letter also indicated that the Company will be provided with a compliance period of 180 calendar days, o

View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Streamex Corp. filing history →

Source: SEC EDGAR

accession 0001185185-23-000961

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.